The evaluation of synthetic strategies for oligonucleotides of defined sequence

Lombardi, Stephen; Seidell, Hollis; Hachmann, John

doi:10.1016/0010-468x(83)90011-9

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there was increased toxicity associated with this combination therapy, this was the first real advance in systemic therapy since the introduction of gemcitabine. More recently, the MPACT Phase III study demonstrated that nab-paclitaxel (albumin-bound paclitaxel) plus gemcitabine led to a significant improvement in overall survival when compared with gemcitabine alone (8.5 vs 6.7 months) [7]. Even with these recent advances in systemic therapies for advanced PDAC, the median survival remains dismally low due to a multitude of factors.…”

mentioning

confidence: 98%

Promising New Therapies in Advanced Pancreatic Adenocarcinomas

Kundranda

Kachaamy

2014

Future Oncol.

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is a lethal disease due to late diagnosis, early metastasis and the lack of effective therapies. In patients with metastatic disease, 1-year survival ranges from 17 to 23% and 5-year survival is less than 5%. This necessitates an urgent need for developing more effective therapies. Targeting the neoplastic cells has been largely ineffective due to the dense stroma, which is a physical barrier for effective drug delivery and also a source for different factors that promote tumor progression and immunosuppression. In this review, we focus on understanding the complex biology of this tumor as it relates to the evaluation of previously failed molecularly targeted trials and review potential new therapies that are emerging in the treatment of metastatic pancreatic ductal adenocarcinoma.

show abstract

mentioning

confidence: 98%